Nasdaq vktx.

SAN DIEGO, CA – March 28, 2023 – Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company’s dual glucagon-like peptide 1 …See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.Stock analysis for Viking Therapeutics Inc (VKTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Viking Therapeutics (NASDAQ:VKTX) spiked in late December, due to recent news indirectly related to the biopharma firm, and its efforts to bring a treatment for non-alcoholic steatohepatitis (or ...

Viking Therapeutics Inc. (VKTX) is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. Metabolic and rare disease programs include novel selective thyroid... VKTX : 12.28 (+6.23%) Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire - Thu Sep 7, 3:05PM CDT.Stock analysis for Viking Therapeutics Inc (VKTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

... Back to VKTX Overview About News Headlines Nasdaq provides updated worldwide news headlines. Here you can find up-to-the-minute news and analysis of the company …

In the last 3 months, 9 analysts have offered 12-month price targets for Viking Therapeutics. The company has an average price target of $33.0 with a high of $40.00 and a low of $24.00. Below is a ...VKTX Related ETFs ; VTI, 0%, +3.43% ; Total Stock Market ETF Vanguard ; DWAS, 0.82%, -2.47% ; DWA Smallcap Momentum Invesco ETF ...Viking Therapeutics (NASDAQ: VKTX) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. This data comes from its Phase 1 study of ...Strong Quarter-End Cash Position of $376M. SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the ...Viking Therapeutics Inc (NASDAQ: VKTX) (after the close) Thursday . Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open) Baxter International Inc (NYSE: BAX) (before the market open)

Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ...

Source: Shutterstock. Viking Therapeutics (NASDAQ: VKTX) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. This data comes from its ...

Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ...Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of $1.05. If an investor was to purchase shares of VKTX stock at the current price ...Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ETCompany ParticipantsStephanie Diaz - Manager of...SAN DIEGO, Oct. 23, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Apr 3, 2023 · SAN DIEGO, April 3, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ... Stock analysis for Viking Therapeutics Inc (VKTX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Fintel reports that on July 27, 2023, HC Wainwright & Co. reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 141.43% Upside. As of ...The latest price target for . Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on Monday, October 2, 2023.The analyst firm set a price target for 32.00 expecting VKTX to rise ...Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, California, is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and ...Dec 4, 2023 · The latest price target for Viking Therapeutics (NASDAQ: VKTX) was reported by Truist Securities on December 4, 2023.The analyst firm set a price target for $32.00 expecting VKTX to rise to within ... VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Pfizer (NYSE:PFE) shares hit a new 52-week low on Friday after announcing that its twice-daily oral weight loss candidate danuglipron will not reach late-stage development as a Phase 2 readout ...Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of $1.05. If an investor was to purchase shares of VKTX stock at the current price ...

Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, California, is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and ...

Fintel reports that on May 8, 2023, HC Wainwright & Co. reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 20.92% Upside. As of ...Viking Therapeutics, Inc. (NASDAQ:VKTX) is a San Diego, California-based biotech company developing therapeutics for patients that are suffering from endocrine and metabolic disorders.Viking Therapeutics' (NASDAQ:VKTX) shares rose 14% after clinical results from a Phase 1 trial on its obesity drug, VK2735, were released. The study showed that VK2735, ...May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease. With ...See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA. VKTX - Viking Therapeutics Inc - Stock screener for …As at June 2022, Viking Therapeutics had cash of US$169m and no debt. In the last year, its cash burn was US$47m. So it had a cash runway of about 3.6 years from June 2022. There's no doubt that ...

Find the latest Viking Therapeutics, Inc. (VKTX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Nasdaq Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access ...

VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...Dec 4, 2023 · The public float for VKTX is 89.39M and currently, short sellers hold a 18.98% ratio of that float. The average trading volume of VKTX on December 04, 2023 was 2.05M shares. VKTX) stock’s latest price update. Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 9.99relation to previous closing price of 13.01. Strong Quarter-End Cash Position of $376M. SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the ...Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ... See the latest Viking Therapeutics Inc stock price (VKTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Here's why they chose Bluebird Bio (NASDAQ: BLUE), Travere Therapeutics (NASDAQ: TVTX), and Viking Therapeutics (NASDAQ: VKTX). The upside is huge, but beware of the risks .Dec 1, 2023 · Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire. Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports.Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered …

SAN DIEGO, Sept. 11, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added 15% on Monday after Roche (OTCQX:RHHBY) agreed to acquire a peer obesity drugmaker Carmot Therapeutics (CRMO) in a up to $3.1B deal ...Nov 13, 2023 · SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ... Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share. All thanks to its potential treatment for obesity, VK2735.Instagram:https://instagram. nyse canobest broker for ipopaper trading accountsmost popular forex trading platform Clinical-stage biotech Viking Therapeutics ( VKTX 6.23%) is having another tough trading session. As of 1:40 p.m. ET Tuesday, Viking's stock was down by 19.8% on higher-than-normal volume ... fiduciary financial advisor houstoncarbon capture companies Shares of Viking Therapeutics ( VKTX 6.23%) were up 89.7% for the week as of Thursday afternoon, after being up as much as 95.5% for the week, according to data provided by S&P Global Market ...As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq. best tax exempt bond funds 21 sept 2023 ... We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate ... There's no doubt that money can be made by owning shares of ...SAN DIEGO, Nov. 28, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...29 mar 2023 ... ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...